PMID- 11604575
OWN - NLM
STAT- MEDLINE
DCOM- 20020508
LR  - 20191105
IS  - 1065-6251 (Print)
IS  - 1065-6251 (Linking)
VI  - 8
IP  - 6
DP  - 2001 Nov
TI  - Cellular therapy: exploiting NK cell alloreactivity in transplantation.
PG  - 355-9
AB  - Allogeneic hematopoietic transplantation relies on T-cell alloreactions for 
      engraftment and the graft-versus-leukemia (GVL) effect. In human leukocyte 
      antigen (HLA) haplotype-mismatched transplants, extensive T-cell depletion of the 
      graft is essential to prevent GVHD. This raises the question of whether 
      mismatched transplants exert any GVL effect and whether it will ever be possible 
      to reduce the intensity of preparative regimens. Because natural killer (NK) 
      cells are negatively regulated by MHC class I-specific inhibitory receptors, 
      mismatched transplants may trigger NK-cell alloreactivity. HLA class I 
      disparities driving NK-cell alloreactions in the GVH direction mediate strong GVL 
      effects, produce higher engraftment rates, and do not cause GVHD. In murine 
      MHC-mismatched transplant models with no donor T-cell reactivity against the 
      recipient, the pre-transplant infusion of donor-vs-recipient alloreactive NK 
      cells conditioned the recipients to bone marrow transplantation without GVHD. 
      NK-cell alloreactivity may be a unique therapeutic tool for tolerance induction 
      and clearance of leukemia in hematopoietic transplantation.
FAU - Ruggeri, L
AU  - Ruggeri L
AD  - Division of Hematology and Clinical Immunology, Department of Clinical and 
      Experimental Medicine, University of Perugia, Perugia, Italy.
FAU - Capanni, M
AU  - Capanni M
FAU - Martelli, M F
AU  - Martelli MF
FAU - Velardi, A
AU  - Velardi A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Hematol
JT  - Current opinion in hematology
JID - 9430802
SB  - IM
MH  - Animals
MH  - Graft vs Tumor Effect/immunology
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Killer Cells, Natural/*immunology/transplantation
MH  - Lymphocyte Depletion
MH  - Transplantation, Homologous/immunology
RF  - 35
EDAT- 2001/10/18 10:00
MHDA- 2002/05/09 10:01
CRDT- 2001/10/18 10:00
PHST- 2001/10/18 10:00 [pubmed]
PHST- 2002/05/09 10:01 [medline]
PHST- 2001/10/18 10:00 [entrez]
AID - 10.1097/00062752-200111000-00007 [doi]
PST - ppublish
SO  - Curr Opin Hematol. 2001 Nov;8(6):355-9. doi: 10.1097/00062752-200111000-00007.